All In Biotech

Drug Trial Radar · NCT00782340

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH

Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

263

Actual

Start

Sep 2008

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Chelsea TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Chiltern International Inc.
First posted
Oct 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Conditions

  • Symptomatic Neurogenic Orthostatic Hypotension (NOH)
  • Non-diabetic Neuropathy
  • Primary Autonomic Failure
  • Dopamine Beta Hydroxylase Deficiency

Interventions

  • PlaceboDrug

    100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

  • DroxidopaDrug

    100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Orthostatic Hypotension Questionnaire Score (OHQ)Time frame: 7 days

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • North Alabama Neuroscience

    Huntsville, Alabama

  • Mayo Clinic-Arizona

    Scottsdale, Arizona

  • Arkansas Cardiology

    Little Rock, Arkansas

  • University of California, Irvine

    Irvine, California

  • Bradenton Neurology, Inc

    Bradenton, Florida

  • Suncoast Neuroscience Associates, Inc

    St. Petersburg, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Cncs, Ninds,Nih

    Bethesda, Maryland

  • Nerological Reserch Center at Hattiesburg

    Hattiesburg, Mississippi

  • North Shore Hospital

    Manshasette, New York

  • Pennsylvania Hospital of the University of PA Health System- Department of Neurology

    Philadelphia, Pennsylvania

  • HAN Neurological Associates

    Upland, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • Evergreen Hospital Medical Center; Booth Gardner Parkinson's Care Center

    Kirkland, Washington

  • University of Calgary

    Calgary, Alberta, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • Movment Disorder Clinic Deer lodge Centre

    Winnipeg, Manitoba, Canada

  • David B. King, - Private Clinic

    Halifax, Nova Scotia, Canada

  • London Health Sciences Centre, UH

    London, Ontario, Canada

  • UHNresearch

    Toronto, Ontario, Canada

  • IRCM

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.